Bibliography
Found 32 results
Filters: Keyword is Biomarkers [Clear All Filters]
Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2015 ;69(1):29-35.
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology. 2013 ;81(17):1492-9.
Clinical variables identify seronegative HCV co-infection in HIV-infected individuals. J Clin Virol. 2011 ;52(4):328-32.
Exosome markers associated with immune activation and oxidative stress in HIV patients on antiretroviral therapy. Sci Rep. 2018 ;8(1):7227.
. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology. 2009 ;73(23):1982-7.
. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment. PLoS One. 2016 ;11(6):e0157160.
When do models of NeuroAIDS faithfully imitate "the real thing"?. J Neurovirol. 2018 ;24(2):146-155.
. Plasma (1 → 3)-β-D-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis. J Neurovirol. 2019 ;25(6):837-843.
Vascular injury markers associated with cognitive impairment in people with HIV on suppressive antiretroviral therapy. AIDS. 2023 ;37(14):2137-2147.
. . Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. J Neurovirol. 2016 ;22(4):479-87.
Predictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CART. Journal of NeuroVirology [Internet]. 2014 ;20(3):294-303. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24696364
Genome-wide association study of HIV-associated neurocognitive disorder (HAND): A CHARTER group study. Am J Med Genet B Neuropsychiatr Genet. 2017 ;174(4):413-426.
Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection. Mol Neurobiol. 2019 ;56(5):3808-3818.
Monocyte Activation Markers in Cerebrospinal Fluid Are Associated with Impaired Neurocognitive Testing in Advanced HIV Infection. In: AAN Meeting. AAN Meeting. New Orleans, Louisiana; 2012. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22569268
. Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy. Clin Infect Dis. 2018 ;67(5):770-777.
Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV. J Neurovirol. 2016 ;22(4):431-41.
. A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. J Neuroimmune Pharmacol. 2013 ;8(5):1123-35.
. Is the glass three-quarters full or one-quarter empty?. J Infect Dis. 2006 ;194(12):1628-31.
. The complement system, neuronal injury, and cognitive function in horizontally-acquired HIV-infected youth. J Neurovirol. 2016 ;22(6):823-830.
. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals. J Neurovirol. 2019 ;25(2):150-161.
Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease. J Neurovirol. 2019 ;25(5):702-709.
.